一种强大的NLRP3抑制剂,对MCC950敏感性和耐药性炎症有效
Wonyoung Kim1, Soyeon Kim1, Hawon Woo1
1Department of Biological Sciences, College of Natural Science, Seoul National University, Seoul 08826, South Korea.
Cell chemical biology
|September 10, 2025
概括
研究人员发现ZAP-180013是一种强大的NLRP3炎症酶的小分子抑制剂. 这种化合物在细胞和动物模型中有效减少炎症,显示出治疗炎症性疾病的前景.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- NLRP3炎症酶是炎症反应的关键调解者,检测病原体和损伤相关的分子模式.
- 失调的NLRP3激活与各种疾病有关,包括炎症性疾病,代谢疾病和癌症.
- 准NLRP3为许多炎症状况提供了治疗策略.
研究的目的:
- 确定和描述NLRP3炎症体的新型小分子抑制剂.
- 在炎症的临床前模型中评估ZAP-180013的疗效.
主要方法:
- 高通量化学选以确定NLRP3抑制剂.
- 分子对接和局部定向突变发生,以确定ZAP-180013.3的结合部位.
- 在体外测试中使用人类髓状细胞来评估炎症酶抑制.
- 用小鼠模型进行体内研究,以评估治疗潜力.
主要成果:
- ZAP-180013被确定为一种强效和选择性的NLRP3抑制剂.
- 分子对接和实验验证证证实ZAP-180013在NLRP3.3中与H698结合.
- 在人类细胞中,ZAP-180013抑制了NLRP3炎症酶激活,包括MCC950耐药变体.
- 在小鼠中,ZAP-180013的全身治疗减少了皮肤炎症和LPS诱导的细胞因子反应.
结论:
- ZAP-180013是一种强效和选择性的NLRP3抑制剂,在临床前模型中已证明有效性.
- 这种抑制剂显示出治疗炎症性疾病的潜力,包括那些对其他疗法的耐药性.
- ZAP-180013代表了NLRP3介导的炎症状况的有前途的治疗候选者.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...


